Market Place
Sourcing Support
Ex-CinCor CEO Marc de Garidel lands at Abivax after negotiating $1.8B cash sale
06 Apr 2023 //
ENDPTS
AstraZeneca Acquires CinCor for $1.3B Upfront
03 Mar 2023 //
CONTRACT PHARMA
CinCor Announces Receipt of Minutes with FDA on Planned PIII of Baxdrostat
21 Feb 2023 //
GLOBENEWSWIRE
AstraZeneca eagerness for CinCor revealed in larger first offer
24 Jan 2023 //
FIERCE BIOTECH
How the price of AstraZeneca`s buyout of Cincor fell by $1.4B
23 Jan 2023 //
ENDPTS
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
23 Jan 2023 //
BUSINESSWIRE
AstraZeneca to acquire CinCor Pharma in nearly $2 billion deal
10 Jan 2023 //
PRESS RELEASE
CinCor Pharma to be Acquired by AstraZeneca
09 Jan 2023 //
GLOBENEWSWIRE
CinCor`s hypertension drug loses halo after phase 2 fail
29 Nov 2022 //
FIERCEBIOTECH
CinCor Announces Topline Data for Phase 2 HALO Trial Evaluating Baxdrostat
28 Nov 2022 //
GLOBENEWSWIRE
CinCor Pharma to Present at Piper Sandler and Evercore ISI Conferences
22 Nov 2022 //
GLOBENEWSWIRE
CinCor Pharma to Present at Upcoming Jefferies London Healthcare Conference
09 Nov 2022 //
PRESS RELEASE
CinCor Pharma Appoints Michael W. Kalb, Executive VP and CFO
07 Nov 2022 //
PRESS RELEASE
CinCor Pharma Announces Publication in the NEM of Phase 2 BrigHtn Data
07 Nov 2022 //
GLOBENEWSWIRE
CinCor Announces Late-Breaking Presentation of Pha2 BrigHtn Data on Baxdrostat
07 Nov 2022 //
GLOBENEWSWIRE
CinCor Reports Third Quarter Financial Results and Provides Corporate Update
03 Nov 2022 //
GLOBENEWSWIRE
CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat
25 Oct 2022 //
GLOBENEWSWIRE
CinCor Announces Publication of Phase 1 Multiple Ascending Dose Study Data
21 Oct 2022 //
GLOBENEWSWIRE
CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat
12 Oct 2022 //
CINCOR
CinCor Pharma Announces Late-Breaking Presentation of Ph2 Data for Baxdrostat
28 Sep 2022 //
GLOBENEWSWIRE
CinCor Pharma to Participate at Upcoming September Investor Conferences
31 Aug 2022 //
PRESS RELEASE
CinCor Announces Presentation of Phase 1 Clinical Data for Baxdrostat
22 Aug 2022 //
GLOBENEWSWIRE
CinCor Pharma Announces Closing of Upsized Public Offering
15 Aug 2022 //
GLOBENEWSWIRE
CinCor raises $225M on back of positive PhII readout
11 Aug 2022 //
ENDPOINTS NEWS
CinCor Pharma Announces Pricing of Upsized Public Offering
10 Aug 2022 //
GLOBENEWSWIRE
CinCor Pharma Announces +ve Topline Data for PII BrigHtn Trial of Baxdrostat
08 Aug 2022 //
GLOBENEWSWIRE
CinCor Reports Second Quarter Financial Results and Provides Corporate Update
08 Aug 2022 //
GLOBENEWSWIRE
CinCor Pharma Announces Proposed Public Offering of Common Stock
08 Aug 2022 //
GLOBENEWSWIRE
CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial
26 Jul 2022 //
PRESS RELEASE
CinCor Pharma Doses First Patient in PII FigHTN-CKD Trial Evaluating CIN-107
01 Jun 2022 //
GLOBENEWSWIRE
CinCor Pharma to Present at the Jefferies Healthcare Conference
31 May 2022 //
GLOBENEWSWIRE
CinCor Pharma to Present at Upcoming Investor Conferences
17 May 2022 //
GLOBENEWSWIRE
CinCor Reports First Quarter Financial Results and Provides Corporate Update
10 May 2022 //
GLOBENEWSWIRE
CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit
19 Apr 2022 //
GLOBENEWSWIRE
CinCor Reports Q4 & Full-Year 2021 Financial Results; Provides Corporate Update
22 Mar 2022 //
GLOBENEWSWIRE
CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
17 Mar 2022 //
GLOBENEWSWIRE
CinCor Pharma to Report Q4 and FY 2021 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference
03 Mar 2022 //
GLOBENEWSWIRE
CinCor Pharma Appoints June Lee to Its Board of Directors
13 Jan 2022 //
PRESS RELEASE
As three biotechs head to Wall Street, a battered sector braces for a pullback
07 Jan 2022 //
BIOPHARMADIVE
CinCor Pharma Announces Pricing of Initial Public Offering
06 Jan 2022 //
PRESS RELEASE
CinCor Pharma Launches Roadshow for Proposed Initial Public Offering of Common Stock
03 Jan 2022 //
PRESS RELEASE
CinCor Doses First Patient in HALO, a Phase 2 Clinical Trial
09 Dec 2021 //
GLOBENEWSWIRE
CinCor Pharma Appoints Terry Coelho as Executive Vice President, CFO
28 Oct 2021 //
GLOBENEWSWIRE
CinCor Pharma makes bags $143M; plans for blood pressure drug
13 Oct 2021 //
ENDPTS
CinCor Pharma Raises $143 Million in Series B Financing
12 Oct 2021 //
GLOBENEWSWIRE
CinCor Pharma Appoints Marc de Garidel as Chief Executive Officer
06 Jul 2021 //
GLOBENEWSWIRE
CinCor Pharma Announces Appointments of three Members to Its Board of Directors
20 May 2021 //
GLOBENEWSWIRE
